A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph plus chronic myeloid leukemia (CML) patients


Baccarani M., Castagnetti F., Porkka K., Nielsen J. L. , Hjorth-Hansen H., Haznedaroglu I., ...More

49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 8 - 11 December 2007, vol.110 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 110
  • City: Georgia
  • Country: United States Of America